🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Jean Bernard Marc

Gheskio Centers

ORCID: 0009-0008-1428-5015

MedicineImmunology and Microbiology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “A 3-month clofazimine–rifapentine-containing regimen for drug-susceptible tuberculosis versus standard of care (Clo-Fast): a randomised, open-label, phase 2c clinical trial”.

A 3-month clofazimine–rifapentine-containing regimen for drug-susceptible tuberculosis versus standard of care (Clo-Fast): a randomised, open-label, phase 2c clinical trial

The Lancet Infectious Diseases(2025)10.1016/s1473-3099(25)00436-0

N/A

0.315DataRank · unranked

4 citations

Isabelle R. Weir, Kimberly K. Scarsi, Alberto Mendoza‐Ticona, Samuel Pierre, Luke Hall +30 more

Virological and drug-resistance outcomes for people living with HIV initiating or switching to tenofovir, lamivudine, and dolutegravir in six PEPFAR-supported countries: a prospective cohort study

The Lancet HIV(2025)10.1016/s2352-3018(25)00162-6

N/A

0DataRank · unranked

3 citations

Caitlyn McCarthy, Carole L. Wallis, Cissy Kityo, Michael D. Hughes, Catherine Godfrey +44 more

Virology Outcomes of Tenofovir-lamivudine-dolutegravir in Treatment-naïve and Virologically Suppressed Individuals Switching From an NNRTI-based Regimen: An Observational Analysis at 13 Sites

Open Forum Infectious Diseases(2025)10.1093/ofid/ofaf270

N/A

0DataRank · unranked

1 citations

Caitlyn McCarthy, Serena P. Koenig, Michael D Hughes, Carole L. Wallis, Isaac Tsikhutsu +41 more